

2 December 2011

ASX Limited  
 Quotations  
 20 Bridge Street  
 Sydney NSW 2000  
[quotations@asx.com.au](mailto:quotations@asx.com.au)

### DISPATCH OF RIGHTS ISSUE HOLDING STATEMENTS

Cellmid Limited wishes to provide information in relation to the ordinary shares issued in connection with the Company's \$0.17 per share rights offer that closed recently. The following information is provided as requested:

- 23,560,944 ordinary shares were issued in respect of acceptances to the closing date of 24 November;
- Holding statements in relation to the shares issued have been dispatched;
- The total capital of the Company following the issue of the 23,560,944 shares is 420,195,073; and
- the 20 largest holdings of the ordinary shares and the percentages held are now as follows:

| <b>Name of shareholder</b>                             | <b>Percentage Held</b> |
|--|------------------------|
| Cell Signals Inc                                       | 7.616                  |
| Seistend Pty Ltd <DW King Super Fund A/C>              | 5.355                  |
| Mr Gregory Glenn Worth <Worth S/F A/C>                 | 4.031                  |
| Vista Partners LLC                                     | 1.904                  |
| Mrs Tania Hill   | 1.568                  |
| Hera Investments Pty Ltd                               | 1.383                  |
| Talrind Pty Ltd <Worth D/T A/C>                        | 1.326                  |
| Mr Christopher Walker                                  | 1.19                   |
| Mr Vincent Patrick Sweeney <Macguire Family Super A/C> | 1.19                   |
| Ms Christine Anne Smith                                | 1.166                  |
| Mr Gregory Bernard Hilton                              | 1.01                   |

|   |       |
|---|-------|
| Labrinto Pty Ltd  | 0.952 |
| Mrs Ellen Margaret Finger   | 0.833 |
| Chamier Endersbee Pty Ltd <Endersbee Family Super A/C>                    | 0.788 |
| Lee Geok Thye (Holdings) SDN BHD  | 0.738 |
| Mr Paul Philip Ranby  | 0.652 |
| Mr Douglas Battersby & Mrs Alison Battersby<br><Veruse Employees S/F A/C> | 0.597 |
| Walleroo Pty Limited <Christopher Walker S/F A/C>                         | 0.595 |
| Agrico Pty Ltd <Palm Super Fund A/C>                                      | 0.595 |
| Computer Skills Pty Ltd <Sunshine Super Fund A/C>                         | 0.571 |

End

Contact:

Maria Halasz, CEO

T +612 9299 0311

#### **Cellmid Limited (ASX: CDY)**

Cellmid is an Australian biotechnology company developing innovative novel therapies and diagnostic tests for inflammatory diseases, heart attack and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally. The Company's most advanced clinical development program is for the treatment of acute myocardial infarction (AMI) utilising the midkine protein. Cellmid is also developing anti-midkine antibodies for the treatment of inflammatory and autoimmune disorders. In addition, Cellmid is commercialising midkine as a biomarker for cancer diagnosis. Elevated midkine concentration in the blood and other body fluids is strongly indicative of cancer. Cellmid's first product, the MK-ELISA, is a blood test that sensitively and accurately measures serum midkine levels.

#### **Midkine (MK)**

Midkine is a multifunctional growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, because midkine is only present in a disease context, targeting midkine does not harm normal healthy tissues.